Dapoxetine Hydrochloride | Dapocare

Take Control of Your Performance

Dapoxetine is a revolutionary solution designed to help men regain control over their sexual performance. Specifically formulated to treat premature ejaculation (PE), it significantly extends the duration of sexual activity, giving you the confidence to perform at your best.

Unlike standard ED medications that focus on blood flow, Dapoxetine works by increasing serotonin levels in the nervous system, delaying the chemical reaction that triggers ejaculation. This allows for better control and prolonged intimacy.

Key Benefits:

• Last Longer: Clinically proven to increase the time before ejaculation by up to 300%.
• Total Control: Helps you manage the moment of climax.
• Rapid Onset: Works quickly, typically within 1-3 hours.
• Confidence Boost: Removes the anxiety of finishing too soon.

Dosage & Usage:
The recommended starting dose is usually 30mg, taken 1 to 3 hours before sexual activity. It can be increased to 60mg if necessary. Do not take more than one dose every 24 hours. Swallow the tablet whole with a full glass of water.

Quality You Can Trust
At Stereo Pro, we guarantee pharmaceutical-grade Dapoxetine by Dapocare with >99% purity. Every batch is lab-tested to ensure you receive a safe and effective product.

Chemical Profile

• Active compound: dapoxetine (chiral tertiary amine; marketed as the S‑enantiomer in clinical formulations).
• Structural class: short‑acting phenylpropylamine derivative with a tertiary N,N‑dimethylamine moiety and an aromatic (naphthyl/phenyl) ether/aryl substituent on the propyl chain. The molecule contains a single stereogenic center (S‑configuration in clinically used material).
• Physicochemical properties: lipophilic, highly protein‑bound in plasma. The free base has modest aqueous solubility; pharmaceutical salts (e.g., hydrochloride) are used to improve formulation properties.
• Molecular weight and formula: reported values vary with salt form; the free base is in the low 300s g·mol−1 range (for clinical work use the label‑specified value for the formulated salt).
• Half‑life: rapid systemic elimination of the parent drug with an elimination half‑life (t1/2) of the parent compound typically reported at approximately 1.5–2 hours after oral dosing. Metabolic products (desmethylated and other oxidative metabolites) exhibit substantially longer terminal half‑lives (on the order of ~15–20 hours for major metabolites), but these metabolites have markedly lower pharmacologic activity compared with the parent.

Clinical Pharmacology

• Mechanism of action: dapoxetine is a selective serotonin reuptake inhibitor (SSRI) with high affinity for the serotonin transporter (SERT). By inhibiting SERT, dapoxetine increases synaptic 5‑hydroxytryptamine (5‑HT, serotonin) concentrations in central nervous system pathways that regulate ejaculatory latency. Enhanced serotonergic neurotransmission in supraspinal and spinal ejaculatory circuits augments inhibitory control over the ejaculatory reflex, an effect mediated primarily via 5‑HT1B and 5‑HT2C receptor subtypes in preclinical and clinical pharmacology models.
• Selectivity and receptor profile: dapoxetine demonstrates a high degree of selectivity for SERT over norepinephrine and dopamine transporters; it does not display clinically significant direct agonist or antagonist activity at major neurotransmitter receptors at therapeutic concentrations.
• Pharmacokinetics (key points):
  • Absorption: rapid oral absorption with Tmax typically around 1 hour (range ~0.5–2 hours). Food can alter absorption kinetics; the clinical effect profile is related to the rapid onset and short systemic exposure of the parent compound.
  • Distribution: dapoxetine is highly protein‑bound in plasma (high percent bound), yielding extensive distribution into tissues consistent with a lipophilic aromatic amine.
  • Metabolism: extensively metabolized in the liver primarily via cytochrome P450 enzymes, notably CYP3A4 and CYP2D6 (with contribution from other isoforms). Major metabolic pathways include N‑demethylation and oxidative pathways leading to metabolites that are pharmacologically less active or inactive.
  • Elimination: excreted predominantly as metabolites in urine, with a smaller proportion recovered in feces. The parent compound is rapidly cleared; most systemic exposure after dosing represents metabolites at later time points.
• Pharmacodynamic considerations: the short systemic half‑life of the parent molecule distinguishes dapoxetine from longer‑acting SSRIs; its acute pharmacokinetic profile (rapid rise and fall of plasma concentrations) supports an on‑demand dosing strategy in approved indications. Plasma exposure is increased by inhibitors of CYP3A4/CYP2D6 and decreased by strong inducers; patient factors affecting CYP2D6 phenotype may alter exposure to parent drug and metabolites.

Storage & Stability

• Dosage form considerations: dapoxetine is supplied in solid oral dosage forms (tablets) of formulated salt. Stability is formulation dependent; stability-indicating studies for the marketed formulation determine official shelf‑life.
• Recommended storage conditions (typical pharmaceutical guidance): store in a cool, dry place protected from excessive light and moisture; maintain within recommended controlled room temperature ranges (commonly 15–30 °C) unless the product label specifies otherwise.
• Container and handling: retain in original tight, light‑resistant container until dispensed; protect from high humidity and heat. Avoid freezing. Follow the manufacturer’s or regulatory label for specific storage duration and expiry dating.
• Degradation: as with many aromatic amines and lipophilic compounds, degradation pathways include oxidative transformation of aromatic moieties and hydrolysis under extreme conditions; formulation stabilizers and appropriate packaging reduce such risks.

General Information

• Primary clinical indication: dapoxetine is indicated for the treatment of premature ejaculation in adult men (labeling and approved indications vary by regulatory jurisdiction). Its therapeutic effect is achieved through acute augmentation of serotonergic inhibition of the ejaculatory reflex.
• Clinical context and limitations: dapoxetine was developed as a rapid‑onset, short‑duration SSRI suitable for on‑demand use; it is not used as a chronic antidepressant due to its pharmacokinetic profile. Efficacy and tolerability are dose‑ and patient‑dependent; drug–drug interactions (notably with CYP3A4 and CYP2D6 inhibitors) and comorbid conditions need to be considered in clinical use.
• Research and off‑label notes: earlier development explored dapoxetine as an antidepressant, but the current clinical application is focused on sexual dysfunction (premature ejaculation) because of its pharmacodynamic and pharmacokinetic characteristics.